The FDA’s approval of the first point-of-care total PSA test for prostate cancer has the potential to improve patient care by streamlining PSA testing. However, a Clinical Laboratory Improvement Amendments waiver is needed before this test can be fully integrated into clinical care.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Monosaccharide-mediated rational synthesis of a universal plasmonic platform with broad spectral fluorescence enhancement for high-sensitivity cancer biomarker analysis
Journal of Nanobiotechnology Open Access 10 April 2022
-
A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection
Microsystems & Nanoengineering Open Access 05 March 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
U.S. Food and Drug Administration. Recently-approved devices: Sangia Total PSA Test - P170037. FDA https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm630197.htm (updated 31 Jan 2019).
U.S. Food and Drug Administration. Summary of safety and effectiveness data (SSED). FDA https://www.accessdata.fda.gov/cdrh_docs/pdf17/p170037b.pdf (2019).
OPKO Diagnostics. Instructions for use. FDA https://www.accessdata.fda.gov/cdrh_docs/pdf17/p170037c.pdf (2019).
Loeb, S. et al. How active is active surveillance? Intensity of followup during active surveillance for prostate cancer in the United States. J. Urol. 196, 721–726 (2016).
Centers for Medicare & Medicaid Services. Clinical laboratory improvement amendments (CLIA). CMS https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/index.html?redirect=/clia (updated 24 Feb 2019).
Centers for Medicare & Medicaid Services. How to obtain a CLIA certificate of waiver. CMS https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/downloads/HowObtainCertificateofWaiver.pdf (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Meyer, A.R., Gorin, M.A. First point-of-care PSA test for prostate cancer detection. Nat Rev Urol 16, 331–332 (2019). https://doi.org/10.1038/s41585-019-0179-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-019-0179-1
This article is cited by
-
Monosaccharide-mediated rational synthesis of a universal plasmonic platform with broad spectral fluorescence enhancement for high-sensitivity cancer biomarker analysis
Journal of Nanobiotechnology (2022)
-
A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection
Microsystems & Nanoengineering (2021)